Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 15,500 shares, a growth of 49.0% from the August 15th total of 10,400 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is currently 1.7 days.
Wall Street Analyst Weigh In
ANL has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Adlai Nortye in a report on Wednesday, September 4th. They issued a “buy” rating and a $9.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Adlai Nortye in a research report on Thursday, June 20th.
Read Our Latest Stock Report on Adlai Nortye
Hedge Funds Weigh In On Adlai Nortye
Adlai Nortye Stock Up 16.8 %
ANL opened at $2.29 on Monday. The company has a fifty day moving average price of $3.05 and a two-hundred day moving average price of $6.82. Adlai Nortye has a 52 week low of $1.90 and a 52 week high of $19.30.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- Find and Profitably Trade Stocks at 52-Week Lows
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.